Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

Bayer has announced additional cost-cutting measures of EUR 1.5 billion ($1.76 billion) by 2024 to address headwinds encountered in its crop sciences and pharmaceutical businesses that were attenuated by the COVID-19 pandemic.The additional...

Belén Garijo, currently Deputy Chief Executive Officer (CEO), CEO Healthcare, and Vice Chair of the Executive Board of Merck KGaA, has been named as the company’s new Chair of the Executive Board and CEO, effective May 1, 2021. Stefan Oschmann,...

Roche has acquired Inflazome, a Dublin, Ireland-based company developing inflammasome inhibitors for treating chronic inflammatory diseases, for EUR 380 million ($443 million) with Inflazome shareholders also eligible to receive additional...

Pfizer has entered into a manufacturing agreement with Vivet Therapeutics, a Paris-based gene-therapy company developing treatments for inherited liver disorders, under which Pfizer will provide clinical supply for a Phase I/II clinical trial...

Valneva, a Saint-Herblain, France-headquartered vaccine company, has entered into an agreement with the UK government to provide up to 190 million doses of its COVID-19 vaccine candidate, VLA2001, over a five-year period, in a deal worth up to $1.6...

Novavax, a Gaithersburg, Maryland-based clinical-stage vaccine company, has amended a previous agreement with the Serum Institute of India (SII), a Pune, Maharashtra, India-based vaccine manufacturer, under which SII will produce the antigen...

Takeda has opened a new 24,000-square-foot R&D and clinical cell-therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts. The facility will produce cell therapies for clinical evaluation from discovery through Phase...

Merck & Co. and Seattle Genetics, a Bothell, Washington-headquartered biopharmaceutical company, have formed a collaboration, in a deal worth up to $4.2-billion, for Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody drug...